Shopping Cart 0
Cart Subtotal
USD 0

U.S. HLA Typing Transplant Diagnostics Services Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 3200
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

U.S. HLA typing transplant diagnostics services market by technology will reach USD 431.75 million by 2025 from USD 211.98 million with a CAGR of 9.4% in the forecast period of 2018 to 2025.

The major factors driving the market are technological advancements in HLA typing, increasing number of solid organ and stem cell transplantation procedures, risen research grants, funds, and public-private investments are boosting the growth of the U.S. HLA typing transplant diagnostics services market.

The key market players for U.S. HLA typing transplant diagnostics services market are listed below:

Proimmune Ltd.

Creative Biolabs

Histogenetics LLC

The UCLA Immunogenetics Center

Admera Health

Quick Biology

New York Blood Center

The Sequencing Center

BloodCenter of Wisconsin

Laboratory Corporation of America Holdings

The market is further segmented into:

Technology

End-users

The U.S. HLA typing transplant diagnostics services market is segmented on the basis of technology and end-users. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The U.S. HLA typing transplant diagnostics services market is segmented based on technology into polymerase chain reaction (PCR), and next-generation sequencing (NGS). In 2018, polymerase chain reaction (PCR) is expected to dominate the U.S. HLA typing transplant diagnostics services market with 51.0% market share and is expected to reach USD 217.22 million by 2025, growing at a CAGR of 9.2% in the forecast period 2018 to 2025.

The polymerase chain reaction (PCR) is further sub segmented on the basis of techniques into PCR-SSP (Sequence-Specific Primer), PCR SSOP (Sequence-Specific Oligonucleotide), and PCR-SBT (Sequencing Based Typing). In 2018, PCR-SSP (Sequence-Specific Primer) is expected to dominate the U.S. HLA typing transplant diagnostics services market with 41.7% market share and is expected to reach USD 176.37 million by 2025, growing at a CAGR of 9.1% in the forecast period 2018 to 2025.

The U.S. HLA typing transplant diagnostics services market is segmented on the basis of end users into hospitals, transplant centers, specialty clinics, and academic institutes. In 2018, hospitals is expected to dominate the U.S. HLA typing transplant diagnostics services market with 36.3% market share and is expected to reach USD 159.84 million by 2025, growing at the highest CAGR of 9.7% in the forecast period 2018 to 2025.

Covered in this report

The report covers the present scenario and the growth prospects of the U.S. HLA typing transplant diagnostics services market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Table Of Content

Scope

Table Of Contents

1. Introduction 12

1.1. Objectives Of The Study 12

1.2. Market Definition 12

1.3. Overview Of U.S. Hla Typing Transplant Diagnostics Services Market 12

1.4. Currency And Pricing 13

1.5. Limitation 13

1.6. Markets Covered 14

2. Market Segmentation 15

2.1. Markets Covered 15

2.2. Years Considered For The Study 16

2.3. Currency And Pricing 16

2.4. Research Methodology 17

2.5. Primary Interviews With Key Opinion Leaders 20

2.6. Secondary Sources 21

2.7. Assumptions 21

3. Executive Summary 22

4. Market Overview 24

4.1. Drivers 26

4.1.1. Technological Advancements In Hla Typing 26

4.1.2. Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures 26

4.1.3. Increased Research Grants, Funds, And Public-Private Investments 27

?

4.2. Restraints 28

4.2.1. Weak Reimbursements For Organ Donation And Transplantation Procedures 28

4.2.2. Expensive Ngs And Pcr-Based Devices 28

4.3. Opportunities 29

4.3.1. Rising Healthcare Infrastructure In Emerging Nations 29

4.4. Challenges 30

4.4.1. Significant Gap Between Number Of Organs Donated And Organs Required Annually 30

4.4.2. Lack Of Trained Staff 31

5. Premium Insights 32

6. U.S. Hla Typing Transplant Diagnostics Services Market,

By Technology 34

6.1. Overview 35

6.2. Next-Generation Sequencing (Ngs) 36

6.3. Polymerase Chain Reaction (Pcr) 37

6.3.1. Pcr Ssop (Sequence-Specific Oligonucleotide) 38

6.3.2. Pcr Ssp (Sequence-Specific Primer) 38

6.3.3. Pcr-Sbt (Sequencing Based Typing) 38

7. U.S. Hla Typing Transplant Diagnostics Services Market,

By End-Users 39

7.1. Overview 40

7.2. Specialty Clinics 41

7.3. Hospitals 41

7.4. Transplant Centers 41

7.5. Academic Institutes 42

?

8. U.S. Hla Typing Transplant Diagnostics Services Market, Company Landscape 43

8.1. Company Share Analysis: U.S. 43

9. Company Profiles 44

9.1. Proimmune Ltd. 44

9.1.1. Company Overview 44

9.1.2. Proimmune Ltd.: Company Snapshot 44

9.1.3. Product Portfolio 45

9.1.4. Recent Developments 45

9.2. Creative Biolabs 46

9.2.1. Company Overview 46

9.2.2. Creative Biolabs: Company Snapshot 46

9.2.3. Product Portfolio 46

9.2.4. Recent Developments 46

9.3. Histogenetics Llc 47

9.3.1. Company Overview 47

9.3.2. Histogenetics Llc: Company Snapshot 47

9.3.3. Product Portfolio 47

9.3.4. Recent Developments 47

9.4. The Ucla Immunogenetics Center 48

9.4.1. Company Overview 48

9.4.2. The Ucla Immunogenetics Center: Company Snapshot 48

9.4.3. Product Portfolio 48

9.4.4. Recent Developments 48

9.5. Admera Health 49

9.5.1. Company Overview 49

9.5.2. Admera Health: Company Snapshot 49

9.5.3. Product Portfolio 50

9.5.4. Recent Developments 50

9.6. Quick Biology 51

9.6.1. Company Overview 51

9.6.2. Quick Biology: Company Snapshot 51

9.6.3. Product Portfolio 51

9.6.4. Recent Developments 51

9.7. New York Blood Center 52

9.7.1. Company Overview 52

9.7.2. New York Blood Center: Company Snapshot 52

9.7.3. Product Portfolio 52

9.7.4. Recent Developments 52

9.8. The Sequencing Center 53

9.8.1. Company Overview 53

9.8.2. The Sequencing Center: Company Snapshot 53

9.8.3. Product Portfolio 54

9.8.4. Recent Developments 54

9.9. Bloodcenter Of Wisconsin 55

9.9.1. Company Overview 55

9.9.2. Bloodcenter Of Wisconsin: Company Snapshot 55

9.9.3. Product Portfolio 55

9.9.4. Recent Developments 55

9.10. Laboratory Corporation Of America Holdings 56

9.10.1. Company Overview 56

9.10.2. Laboratory Corporation Of America Holdings: Revenue Analysis 56

9.10.3. Product Portfolio 57

9.10.4. Recent Developments 57

?

9.11. Thermo Fisher Scientific Inc. 58

9.11.1. Company Overview 58

9.11.2. Thermo Fisher Scientific Inc. :Revenue Analysis 58

9.11.3. Product Portfolio 59

9.11.4. Recent Developments 59

10. Related Reports 60


List Of Figure

Figures List

Figure 1 U.S. Hla Typing Transplant Diagnostics Services Market: Segmentation 15

Figure 2 U.S. Hla Typing Transplant Diagnostics Services Market:

Data Triangulation 17

Figure 3 U.S. Hla Typing Transplant Diagnostics Services Market:

Research Snapshot 18

Figure 4 U.S. Hla Typing Transplant Diagnostics Services Market:

Bottom Up Approach 19

Figure 5 U.S. Hla Typing Transplant Diagnostics Services Market:

Top Down Approach 19

Figure 6 U.S. Hla Typing Transplant Diagnostics Services Market:

Interview Demographics 20

Figure 7 U.S. Hla Typing Transplant Diagnostics Services Market: Segmentation 23

Figure 8 Drivers, Restraints, Opportunities, And Challenges Of

U.S. Hla Typing Transplant Diagnostics Services Market 25

Figure 9 Healthcare Expenditure In Few Emerging Countries

(2000, 2010 & 2014) 29

Figure 10 Number Of Donors, Recipeints And Waiting Patients In

U.S. From 2010 To 2015 30

Figure 11 Technological Advancements In Hla Typing, Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures Are Expected To Drive The Market For U.S. Hla Typing Transplant Diagnostics Services In The Forecast Period 2018 To 2025 32

Figure 12 Polymerase Chain Reaction (Pcr) Segment Is Expected To Account For The Largest Share Of The U.S. Hla Typing Transplant Diagnostics Services Market In 2018 & 2025 33

Figure 13 U.S. Hla Typing Transplant Diagnostics Services Market:

By Technology, 2017% 35

Figure 14 U.S. Hla Typing Transplant Diagnostics Services Market:

By End-Users, 2017% 40

Figure 15 U.S. Hla Typing Transplant Diagnostics Services Market:

Company Share 2017 (%) 43


List Of Table

Table List

Table 1 U.S. Hla Typing Transplant Diagnostics Services Market,

By Technology, 2016- 2025 (Usd Million) 36

Table 2 U.S Hla Typing Transplant Diagnostics Services Market, Asp (Usd) 36

Table 3 U.S. Hla Typing Transplant Diagnostics Services Market, Polymerase Chain Reaction (Pcr), By Technique, 2016-2025 (Usd Million) 37

Table 4 U.S. Hla Typing Transplant Diagnostics Services Market,

By End-Users, 2016-2025 (Usd Million) 41

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Proimmune Ltd.

Creative Biolabs

Histogenetics LLC

The UCLA Immunogenetics Center

Admera Health

Quick Biology

New York Blood Center

The Sequencing Center

BloodCenter of Wisconsin

Laboratory Corporation of America Holdings